CRO Stock Overview
Operates as a pharmaceutical service and contract research company in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
hVIVO plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.26 |
| 52 Week High | UK£0.37 |
| 52 Week Low | UK£0.19 |
| Beta | 0.97 |
| 11 Month Change | -19.88% |
| 3 Month Change | -21.82% |
| 1 Year Change | 35.79% |
| 33 Year Change | 29.65% |
| 5 Year Change | 303.13% |
| Change since IPO | 322.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| CRO | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -14.0% | 3.9% | 0.8% |
| 1Y | 35.8% | 5.4% | 9.1% |
Return vs Industry: CRO exceeded the German Life Sciences industry which returned 3.6% over the past year.
Return vs Market: CRO exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| CRO volatility | |
|---|---|
| CRO Average Weekly Movement | 8.6% |
| Life Sciences Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CRO's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CRO's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 274 | Mo Khan | www.hvivo.com |
hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom. The company is involved in testing of vaccines and antivirals using human challenge clinical trials; and offers laboratory services, including assay development, cell based assays, compound efficacy and VRM, field trial bio-logistics, molecular, and biomarker analysis services. It provides services to big pharma and biotech organizations.
hVIVO plc Fundamentals Summary
| CRO fundamental statistics | |
|---|---|
| Market cap | €162.94m |
| Earnings (TTM) | €20.89m |
| Revenue (TTM) | €80.48m |
7.8x
P/E Ratio2.0x
P/S RatioIs CRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRO income statement (TTM) | |
|---|---|
| Revenue | UK£67.21m |
| Cost of Revenue | UK£50.65m |
| Gross Profit | UK£16.56m |
| Other Expenses | -UK£884.00k |
| Earnings | UK£17.45m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.026 |
| Gross Margin | 24.64% |
| Net Profit Margin | 25.96% |
| Debt/Equity Ratio | 0% |
How did CRO perform over the long term?
See historical performance and comparison